Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?

Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial

(2017) Arnaud Olivier et al.   EUROPEAN JOURNAL OF HEART FAILURE

Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats

(2016) G Youcef et al.   BRITISH JOURNAL OF PHARMACOLOGY

Efficiencies of platform clinical trials: A vision of the future

(2016) Benjamin R Saville et al.   Clinical Trials

Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study

(2016) Ken Lee Chin et al.   EUROPEAN JOURNAL OF HEART FAILURE

A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis

(2016) Nicolas Girerd et al.   EUROPEAN JOURNAL OF HEART FAILURE

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN JOURNAL OF HEART FAILURE

2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

(2016) Clyde W. Yancy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Genome-Wide Association of CKD Progression: The Chronic Renal Insufficiency Cohort Study

(2016) Afshin Parsa et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Adaptive Designs for Clinical Trials

(2016) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and Design of the ATHENA-HF Trial

(2016) Javed Butler et al.   JACC-Heart Failure

A Systematic Assessment of Absolute Treatment Effect

(2015) João Pedro Ferreira et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials

(2015) Yanmei Chen et al.   BMC Medicine

Obesity and the Obesity Paradox in Heart Failure

(2015) Pritha P. Gupta et al.   CANADIAN JOURNAL OF CARDIOLOGY

Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of SpironolactoneClinical Perspective

(2015) Amil M. Shah et al.   CIRCULATION

Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect

(2015) João Pedro Ferreira et al.   Clinical Research in Cardiology

Review of heart failure treatment in type 2 diabetes patients: It's at least as effective as in non-diabetic patients!

(2015) N. Girerd et al.   DIABETES & METABOLISM

Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial

(2015) Nicolas Girerd et al.   EUROPEAN HEART JOURNAL

Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction

(2015) Scott D. Solomon et al.   EUROPEAN HEART JOURNAL

Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)

(2015) Jane A. Cannon et al.   EUROPEAN JOURNAL OF HEART FAILURE

Geographic differences in heart failure trials

(2015) João Pedro Ferreira et al.   EUROPEAN JOURNAL OF HEART FAILURE

Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial

(2015) Stefan D. Anker et al.   EUROPEAN JOURNAL OF HEART FAILURE

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors

(2015) Bertram Pitt et al.   EUROPEAN JOURNAL OF HEART FAILURE

To the Editor— Diabetes and sudden death: Let’s assess the absolute risk increase rather than the proportional risk from sudden cardiac death!

(2015) Stefano Coiro et al.   HEART RHYTHM

Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure

(2015) Lauren B. Cooper et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Platform Trial

(2015) Scott M. Berry et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Statistical Controversies in Reporting of Clinical Trials

(2015) Stuart J. Pocock et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

(2015) Matthew R. Weir et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic Review

(2015) Ambarish Pandey et al.   Journal of the American Heart Association

Heart failure with systolic dysfunction complicating acute myocardial infarction – differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial

(2014) Sylvain Carillo et al.   Archives of Cardiovascular Diseases

Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction

(2014) Amil M. Shah et al.   Circulation-Heart Failure

Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist

(2014) Orly Vardeny et al.   Circulation-Heart Failure

The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology

(2014) Paulus Kirchhof et al.   EUROPEAN HEART JOURNAL

Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia

(2014) Mikhail Kosiborod et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Spironolactone for Heart Failure with Preserved Ejection Fraction

(2014) Bertram Pitt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure

(2013) Orly Vardeny et al.   Circulation-Heart Failure

Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy

(2013) Patrick Rossignol et al.   Circulation-Heart Failure

Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors

(2013) João Pedro Ferreira et al.   Clinical Research in Cardiology

Post-hoc data analysis

(2013) Douglas Curran-Everett et al.   Current Opinion in Allergy and Clinical Immunology

The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial

(2013) Timothy J. Collier et al.   EUROPEAN HEART JOURNAL

International differences in treatment effect: do they really exist and why?†

(2013) Stuart Pocock et al.   EUROPEAN HEART JOURNAL

Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure

(2013) João Pedro Ferreira et al.   European Journal of Internal Medicine

Natriuretic Peptide–Based Screening and Collaborative Care for Heart Failure

(2013) Mark Ledwidge et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Number needed to treat from absolute risk and incidence rate: How to make apples and oranges comparable?

(2013) Nicolas Girerd et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function

(2013) Romain Eschalier et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The Impact of Complete Revascularization on Long-Term Survival Is Strongly Dependent on Age

(2012) Nicolas Girerd et al.   ANNALS OF THORACIC SURGERY

Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure

(2012) Orly Vardeny et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure

(2012) Karl Swedberg et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Risk-guided therapy: a first step to personalized medicine

(2012) Faiez Zannad et al.   European Journal of Preventive Cardiology

Subgroup analyses of clinical effectiveness to support health technology assessments

(2011) Marie-Ange Paget et al.   PHARMACEUTICAL STATISTICS

Aldosterone Receptor Antagonists

(2010) Bradley A. Maron et al.   CIRCULATION

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial†

(2009) Chris Adamopoulos et al.   EUROPEAN JOURNAL OF HEART FAILURE

Body mass index and mortality in heart failure: A meta-analysis

(2008) Antigone Oreopoulos et al.   AMERICAN HEART JOURNAL